GlassScriptPhysician profile
Stacey A Pniewski
NPI 1770710998
$5,260.07
in general payments reported to CMS, 2019-2025
45 companies · $637 in 2025
The $637 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,165 · 2022: $1,572 · 2023: $789 · 2024: $1,098 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $693.62 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $530.34 | 2022-2024 | Nuplazid |
| Astellas Pharma US INC | $344.22 | 2021-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $307.50 | 2021-2022 | |
| Lilly USA, LLC | $296.65 | 2021-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $276.71 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Jazz Pharmaceuticals INC. | $253.59 | 2022-2023 | |
| Ibsa Pharma INC. | $201.95 | 2021-2025 | Tirosint, Licart, Tirosint |
| Sumitomo Pharma America, INC. | $201.85 | 2024-2025 | Gemtesa, Myfembree, Aptiom |
| Astrazeneca Pharmaceuticals LP | $190.49 | 2021-2022 | |
| Amgen INC. | $172.67 | 2021-2022 | |
| Pfizer INC. | $138.33 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.95 | 2021-2023 | |
| Axsome Therapeutics, INC. | $131.52 | 2023-2024 | Auvelity |
| Aimmune Therapeutics, INC. | $124.99 | 2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Pniewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.